1
|
Mwacalimba K, Sheehy J, Adolph C, Savadelis M, Kryda K, Poulsen Nautrup B. A review of moxidectin vs. other macrocyclic lactones for prevention of heartworm disease in dogs with an appraisal of two commercial formulations. Front Vet Sci 2024; 11:1377718. [PMID: 38978634 PMCID: PMC11229481 DOI: 10.3389/fvets.2024.1377718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Accepted: 06/04/2024] [Indexed: 07/10/2024] Open
Abstract
Macrocyclic lactones (MLs) are the only drug class currently licensed for heartworm disease prophylaxis. Macrocyclic lactones kill third- and fourth-stage larvae of Dirofilaria immitis, thus preventing the development of adult worms in dogs, which are responsible for heartworm disease, a potentially life-threatening condition. Despite considerable overlap in terms of endectocide spectrum, several important differences distinguish moxidectin from other MLs. Moxidectin has beneficial pharmacokinetic characteristics, such as a longer half-life and greater tissue distribution compared to ivermectin. Additionally, moxidectin has a greater margin of safety compared to ivermectin in dogs with ABCB1 (previously MDR1) gene-defect, which is commonly recognized in collies and other breeds. Multiple laboratory studies have shown that moxidectin is more effective than other commonly used heartworm preventives against resistant strains of D. immitis. This improved efficacy benefits individual dogs and helps reduce the risk of spreading resistant strains within the community. Despite the presence of proven resistant strains in the United States, non-compliance with preventive measures remains a major factor contributing to the diagnosis of heartworm disease in dogs. In retrospective analyses, the oral moxidectin combination product Simparica Trio® (sarolaner, moxidectin, and pyrantel) was associated with increased compliance, resulting in more time of protection compared to dogs receiving flea/tick and heartworm preventive products separately. Compliance with the extended-release moxidectin injectables ProHeart® 6 and ProHeart® 12 was higher than with monthly heartworm preventives, as they provide 6 months or a full year of protection with one single injection, respectively, and revenues remain in the veterinary clinics as injectable moxidectin cannot be sourced through online retailers.
Collapse
Affiliation(s)
| | - Jenifer Sheehy
- Veterinary Professional Services, Zoetis, Parsippany, NJ, United States
| | | | - Molly Savadelis
- Veterinary Medicine Research and Development, Zoetis, Kalamazoo, MI, United States
| | - Kristina Kryda
- Veterinary Medicine Research and Development, Zoetis, Kalamazoo, MI, United States
| | | |
Collapse
|
2
|
Drag M, Tielemans E, Mitchell E, McCall JW, Targa N, Bruner R, Yoon S, Colley B, Fankhauser B. Safety of an oral combination of moxidectin, afoxolaner, and pyrantel pamoate in dogs. Res Vet Sci 2024; 173:105271. [PMID: 38631075 DOI: 10.1016/j.rvsc.2024.105271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 04/12/2024] [Accepted: 04/12/2024] [Indexed: 04/19/2024]
Abstract
NexGard®PLUS (moxidectin, afoxolaner, and pyrantel pamoate), is an oral combination product for dogs indicated for the prevention of heartworm disease, the treatment and prevention of flea and tick infestations, and the treatment of gastro-intestinal nematode infections. The safety of this product in dogs was evaluated in three studies. Study #1 was a margin-of-safety study conducted in puppies, dosed six times at 28-day intervals at 1X, 3X, or 5X multiples of the maximum exposure dose (equivalent to 24 μg/kg moxidectin, 5 mg/kg afoxolaner, and 10 mg/kg pyrantel). In Study #2, the product was administered to ABCB1-deficient collie dogs at a 1X dose twice at a 28-day interval, and at a 3X or 5X dose once. Study #3 evaluated the safety of the product at 1X and 3X doses administered three times at 4-week intervals, to dogs harboring adult Dirofilaria immitis. In the three studies, the safety was evaluated on the basis of multiple clinical observations and physical examinations, including a complete assessment of toxicity to macrocyclic lactones, and on comprehensive clinical and anatomical pathology evaluations in Study #1. No clinically significant combination product-related effects were observed in any of the three studies. No signs of macrocyclic lactone toxicity were observed in the ABCB1-deficient collie dogs. Some mild and self-resolving instances of emesis or diarrhea were occasionally observed in the 3X and 5X dosed dogs. NexGard® PLUS was demonstrated to be safe following multiple administrations in puppies, in ABCB1-deficient collie dogs, and in microfilaremic dogs infected with adult D. immitis.
Collapse
Affiliation(s)
- Marlene Drag
- Boehringer Ingelheim Animal Health (BI AH), 6498 Jade Rd, Fulton, MO 65251, USA
| | - Eric Tielemans
- Boehringer Ingelheim Animal Health, 29 Avenue Tony Garnier, 69007 Lyon, France.
| | - Elizabeth Mitchell
- Boehringer Ingelheim Animal Health, 1730 Olympic Drive, Athens, GA 30601, USA
| | - John W McCall
- TRS Labs, Inc, 215 Paradise Blvd, Athens, GA 30607, USA
| | - Norba Targa
- Boehringer Ingelheim Animal Health, 1730 Olympic Drive, Athens, GA 30601, USA
| | - Richard Bruner
- Research Pathology Associates, LLC, 401 Augusta Road, Clemson, SC 29631, USA
| | - Stephen Yoon
- Boehringer Ingelheim Animal Health, 1730 Olympic Drive, Athens, GA 30601, USA
| | - Beth Colley
- Boehringer Ingelheim Animal Health (BI AH), 6498 Jade Rd, Fulton, MO 65251, USA
| | - Becky Fankhauser
- Boehringer Ingelheim Animal Health, 1730 Olympic Drive, Athens, GA 30601, USA
| |
Collapse
|
3
|
Sztukowski KE, Yaufman Z, Cook MR, Aarnes TK, Husbands BD. Vincristine-induced adverse events related to body weight in dogs treated for lymphoma. J Vet Intern Med 2024; 38:1686-1692. [PMID: 38563346 PMCID: PMC11099714 DOI: 10.1111/jvim.17063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 03/21/2024] [Indexed: 04/04/2024] Open
Abstract
BACKGROUND Traditional dosing of chemotherapy drugs based on body surface area may overdose small dogs, leading to an increased frequency of adverse events (AEs). HYPOTHESIS/OBJECTIVES Evaluate the frequency of hematologic and gastrointestinal AEs in dogs with newly diagnosed lymphoma treated with vincristine weighing ≤15 kg in comparison to dogs weighing >15 kg. We hypothesized that dogs weighing ≤15 kg would experience a higher frequency of AEs. ANIMALS One hundred and thirty-eight dogs with newly diagnosed lymphoma were treated with vincristine. METHODS A multicenter retrospective study reviewing hematologic data and medical record information. Complete blood counts were performed no more than 24 hours before vincristine administration and then between 4 and 8 days post-administration. Data were evaluated using logistic regression or ordinal logistic regression. RESULTS Thirty-eight dogs weighing ≤15 kg and 100 dogs weighing >15 kg were included. The median vincristine dose for both groups was 0.6 mg/m2. Seventeen (12.3%) instances of neutropenia occurred with no significant difference in overall frequency or grade between groups. Thirty initially asymptomatic substage A dogs (29.4%) experienced gastrointestinal AEs. Because of the widespread use of gastrointestinal supportive care medications, statistical comparison between groups could not be performed. Seven instances of hospitalization occurred (5.0%) and the risk of hospitalization did not differ significantly between groups (P = .37). CONCLUSIONS AND CLINICAL IMPORTANCE Vincristine dosed at ≤0.6 mg/m2 does not increase the risk of hematologic AEs in dogs weighing ≤15 kg.
Collapse
Affiliation(s)
- Keira E. Sztukowski
- Department of Clinical SciencesThe Ohio State University College of Veterinary MedicineColumbusOhioUSA
| | - Zachary Yaufman
- Department of Clinical SciencesThe Ohio State University College of Veterinary MedicineColumbusOhioUSA
- Present address:
Department of Small Animal Clinical SciencesVirginia‐Maryland College of Veterinary MedicineRoanokeVirginiaUSA
| | - Matthew R. Cook
- Nashville Veterinary SpecialistsNashvilleTennesseeUSA
- Present address:
Metropolitan Veterinary HospitalHighland HeightsOhioUSA
| | - Turi K. Aarnes
- Department of Clinical SciencesThe Ohio State University College of Veterinary MedicineColumbusOhioUSA
| | - Brian D. Husbands
- Department of Clinical SciencesThe Ohio State University College of Veterinary MedicineColumbusOhioUSA
| |
Collapse
|
4
|
Morrill K, Chen F, Karlsson E. Comparative neurogenetics of dog behavior complements efforts towards human neuropsychiatric genetics. Hum Genet 2023; 142:1231-1246. [PMID: 37578529 DOI: 10.1007/s00439-023-02580-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 06/02/2023] [Indexed: 08/15/2023]
Abstract
Domestic dogs display a wide array of heritable behaviors that have intermediate genetic complexity thanks to a long history of human-influenced selection. Comparative genetics in dogs could address the scarcity of non-human neurogenetic systems relevant to human neuropsychiatric disorders, which are characterized by mental, emotional, and behavioral symptoms and involve vastly complex genetic and non-genetic risk factors. Our review describes the diverse behavioral "phenome" of domestic dogs, past and ongoing sources of behavioral selection, and the state of canine behavioral genetics. We highlight two naturally disordered behavioral domains that illustrate how dogs may prove useful as a comparative, forward neurogenetic system: canine age-related cognitive dysfunction, which can be examined more rapidly given the attenuated lifespan of dogs, and compulsive disorders, which may have genetic roots in purpose-bred behaviors. Growing community science initiatives aimed at the companion dog population will be well suited to investigating such complex behavioral phenotypes and offer a comparative resource that parallels human genomic initiatives in scale and dimensionality.
Collapse
Affiliation(s)
- Kathleen Morrill
- Bioinformatics and Integrative Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
- Vertebrate Genome Biology, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Morningside Graduate School of Biomedical Sciences UMass Chan Medical School, Worcester, MA, USA.
| | - Frances Chen
- Bioinformatics and Integrative Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA
- Vertebrate Genome Biology, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Elinor Karlsson
- Bioinformatics and Integrative Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA
- Vertebrate Genome Biology, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| |
Collapse
|
5
|
Gedye K, Poole-Crowe E, Shepherd M, Wilding A, Parton K, Lopez-Villalobos N, Cave N. Prevalence of the ABCB1-1Δ gene mutation in a sample of New Zealand Huntaway dogs. N Z Vet J 2023; 71:133-136. [PMID: 36786530 DOI: 10.1080/00480169.2023.2181238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
AIMS To determine the prevalence of the ATP Binding Cassette Subfamily B Member 1-1Δ mutation (ABCB1-1Δ; previously Multidrug Resistance 1 (MDR1) mutation) in a cohort of New Zealand Huntaway dogs. MATERIALS AND METHODS Samples were opportunistically collected from Huntaway dogs (n = 189) from throughout New Zealand. Buccal swabs were collected from 42 Huntaways from the Wairarapa region and 147 blood samples from Huntaways from the Gisborne, Waikato, Manawatū/Whanganui, Hawkes Bay, Canterbury and Otago regions. DNA was extracted from all samples and tested for the presence of the ABCB1-1Δ allele. RESULTS Of 189 Huntaway dogs that were tested, two were found to be heterozygous carriers of the ABCB1-1Δ allele and the remaining 187/189 dogs were homozygous for the wild type allele. No dogs homozygous for the mutation were identified. CONCLUSIONS AND CLINICAL RELEVANCE The results of this study show that the ABCB1-1Δ allele is present in Huntaway dogs. The low prevalence in this convenience sample suggests that the prevalence of this allele in the Huntaway population is likely to be low. We recommend that veterinary clinicians discuss the potential for this mutation in Huntaways with dog owners including the clinical implications for dogs that are homozygous for the mutated allele and the potential for testing for the mutation, as they would do for other known mutations.
Collapse
Affiliation(s)
- K Gedye
- Tāwharau Ora - School of Veterinary Science, Massey University, Palmerston North, New Zealand
| | | | | | | | - K Parton
- Tāwharau Ora - School of Veterinary Science, Massey University, Palmerston North, New Zealand
| | - N Lopez-Villalobos
- School of Agriculture and the Environment, Massey University, Palmerston North, New Zealand
| | - N Cave
- Tāwharau Ora - School of Veterinary Science, Massey University, Palmerston North, New Zealand
| |
Collapse
|
6
|
Barroso MC, Grilo A, Aguiar S, Aires da Silva F, São Braz B. Occurrence of MDR1 1-delta mutation in herding dog breeds in Portugal. Front Vet Sci 2022; 9:990884. [PMID: 36262528 PMCID: PMC9574212 DOI: 10.3389/fvets.2022.990884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Accepted: 09/14/2022] [Indexed: 11/04/2022] Open
Abstract
The impact of drug transporters in veterinary medicine has been recognized in recent years. One of the most well-characterized is the product of the MDR1 gene, P-gp. A 4-bp deletion in the MDR1 gene known since 2001 has been described to affect herding dog breeds. Since many used drugs in veterinary medicine are substrates for P-gp, including the macrocyclic lactones, such as avermectins, this 4-bp deletion causes a pathological condition known as “ivermectin toxicosis.” For this reason, it is important to determine the animal status concerning this mutation. In Portugal, the information of the occurrence of this mutation in our breeds is limited. The aim of the present study was to determine the occurrence of this mutation and evaluate its association with Portuguese and non-Portuguese dog breeds in Portugal. To achieve this, a total of 105 animals were studied for the presence of the MDR1 4-bp deletion, 23 of which were from Barbado da Terceira, 10 from Cão da Serra d'Aires, 55 belonging to breeds known to carry the mutation (Australian Shepperd, Border Collie and others) and 17 to other breeds (Labrador Retriever, Jack Russel, and others). Despite the small sample size, we observed the presence of the MDR1 1—delta mutation in previously described breeds and identified this mutation in Barbado da Terceira breed for the first time.
Collapse
Affiliation(s)
- Maria Cristina Barroso
- CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal
| | - Andreia Grilo
- CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal,Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Lisbon, Portugal
| | - Sandra Aguiar
- CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal,Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Lisbon, Portugal
| | - Frederico Aires da Silva
- CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal,Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Lisbon, Portugal
| | - Berta São Braz
- CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal,Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Lisbon, Portugal,*Correspondence: Berta São Braz
| |
Collapse
|
7
|
Beckers E, Casselman I, Soudant E, Daminet S, Paepe D, Peelman L, Broeckx BJG. The prevalence of the ABCB1-1Δ variant in a clinical veterinary setting: The risk of not genotyping. PLoS One 2022; 17:e0273706. [PMID: 36037240 PMCID: PMC9423603 DOI: 10.1371/journal.pone.0273706] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 08/11/2022] [Indexed: 11/29/2022] Open
Abstract
Multidrug sensitivity is an autosomal recessive disorder in dogs caused by a 4-bp deletion in the ABCB1 gene, often referred to as the ABCB1-1Δ variant. This disease has a high prevalence in some breeds and causes adverse reactions to certain drugs when given in normal doses. Though most dogs known to be at risk are of the collie lineage or were traced back to it, the variant has also been described in several seemingly unrelated breeds. It is generally advised to genotype dogs at risk before treating them. However, there seems to be a discrepancy between the advice and current veterinary practices, as a recent study in Belgium and the Netherlands showed that most veterinarians never order a DNA test. To assess the possible risk of not testing for multidrug sensitivity in a clinical setting, the ABCB1-1Δ variant allele frequency was established in a sample of 286 dogs from a veterinary clinic. This frequency was compared to the allelic frequency in 599 samples specifically sent for genetic testing. While the allelic frequency in the sample for genetic testing was high (21.6%) and in line with the general reports, the allelic frequency in the clinical setting was low (0.2%), demonstrating an enormous difference between laboratory and clinical frequencies. Because of the low frequency of the disease-causing variant in the general clinical population, the risk of encountering a dog displaying multidrug sensitivity despite not genotyping seems to be low. As the variant was only found in an at-risk breed, the current recommendation of routinely genotyping at-risk breeds before treatment seems justified.
Collapse
Affiliation(s)
- Evy Beckers
- Department of Veterinary and Biosciences, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Iris Casselman
- Department of Veterinary and Biosciences, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Emma Soudant
- Department of Veterinary and Biosciences, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Sylvie Daminet
- Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Dominique Paepe
- Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Luc Peelman
- Department of Veterinary and Biosciences, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Bart J. G. Broeckx
- Department of Veterinary and Biosciences, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
- * E-mail:
| |
Collapse
|
8
|
Drag M, Tielemans E, Mitchell E. Safety of oral afoxolaner formulated with or without milbemycin oxime in homozygous MDR1-deficient collie dogs. J Vet Pharmacol Ther 2022; 45:373-379. [PMID: 35536118 PMCID: PMC9543253 DOI: 10.1111/jvp.13064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 03/31/2022] [Accepted: 04/17/2022] [Indexed: 01/20/2023]
Abstract
Afoxolaner, an insecticide and acaricide compound of the isoxazoline class, is available for dogs as an oral ectoparasiticide medicine (NexGard®) and as an oral endectoparasiticide medicine in combination with milbemycin oxime (MO), a macrocyclic lactone (NexGard® Spectra). The safety of these two compounds, alone or in combination, was investigated in homozygous MDR1‐deficient collie dogs, in two studies. Overall, 30 adult collie dogs were treated once orally, 9 with a placebo, 9 with afoxolaner, 6 with MO, and 6 with a combination of afoxolaner and MO. For afoxolaner, the mean investigated dosage corresponded to 3.8 and 4.7 multiples of the maximum recommended therapeutic doses (RTD) in NexGard® and NexGard® Spectra, respectively. For MO, the mean investigated dosage corresponded to 4.7 multiples of the maximum RTD in NexGard® Spectra. Dogs were closely monitored for adverse reactions on the day of treatment and for the following two days. No significant adverse reaction was observed in any dog from the afoxolaner or the afoxolaner + MO groups; in the MO‐only treated group, mild and transient neurological signs were observed during the 4–8 h post‐treatment window. These studies demonstrated a high level of safety of oral afoxolaner, alone or in combination with milbemycin oxime, in homozygous MDR1‐deficient dogs.
Collapse
Affiliation(s)
- Marlene Drag
- Boehringer Ingelheim Animal Health, Missouri Research Center, Fulton, Missouri, USA
| | | | | |
Collapse
|
9
|
Nürnberger D, Wagner L, Müller SF, Leiting S, Leidolf R, Alber J, Hamann M, Geyer J. Detection of the ABCB11930_1931del TC Mutation in Two Suspected Ivermectin-Sensitive Cats and Their Relatives by a Novel TaqMan Allelic Discrimination Assay. Front Vet Sci 2022; 8:808392. [PMID: 35265692 PMCID: PMC8899013 DOI: 10.3389/fvets.2021.808392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 12/07/2021] [Indexed: 11/13/2022] Open
Abstract
The multidrug resistance gene MDR1 (syn. ABCB1) encodes for the multidrug efflux transporter P-glycoprotein (P-gp), which is highly expressed at the blood-brain barrier and protects the brain from potentially neurotoxic compounds, such as ivermectin. MDR1 mutation in dogs is known to be linked to dramatically increased brain accumulation of ivermectin and life-threatening neurological toxicity. The present report describes two suspected ivermectin-sensitive Maine Coon cats, which exhibited neurological toxicity following subcutaneous application of therapeutic doses of ivermectin. Both cats showed a homozygous 2-bp deletion in the MDR1/ABCB1 coding sequence (ABCB11930_1931del TC, syn. MDR1 nt1930(del2)) that had previously been associated with a drug-sensitive phenotype in cats. For cat MDR1 genotyping, a novel TaqMan allelic discrimination assay was established and validated. This assay was used for ABCB11930_1931del TC genotyping of the drug-sensitive cats as well as of more than 50 relatives. About half of them had the heterozygous MDR1(+/-) genotype, while none of these related cats with former ivermectin treatment had a history of drug-sensitivity. In conclusion: The present study supports previous findings on drug-sensitivity in cats with homozygous ABCB11930_1931del TC mutation. The newly established TaqMan allelic discrimination assay provides a useful and reliable method for routine MDR1 genotyping in cats in order to identify drug-sensitive cats prior to treatment with established P-gp substrates such as ivermectin and other macrocyclic lactones and thus to improve therapeutic safety.
Collapse
|
10
|
Lerdkrai C, Phungphosop N. Prevalence of the MDR1 gene mutation in herding dog breeds and Thai Ridgebacks in Thailand. Vet World 2021; 14:3015-3020. [PMID: 35017851 PMCID: PMC8743763 DOI: 10.14202/vetworld.2021.3015-3020] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 10/20/2021] [Indexed: 12/24/2022] Open
Abstract
Background and Aim: A canine multi-drug resistance 1 (MDR1) nt230(del4) is a well-known inherited disorder that primarily affects collies and various herding breeds. The most recognized clinical implication for affected dogs is associated with an increased risk of multiple drug toxicity. To date, MDR1 gene mutations have been identified globally, especially in dogs from the USA and European countries. This study aimed to investigate the prevalence of MDR1 nt230(del4) in herding dog breeds and Thai Ridgebacks in Thailand. Materials and Methods: We clarified the prevalence of MDR1 nt230(del4) in 263 dogs of eight purebred dog breeds in Thailand using an allele-specific multiplex polymerase chain reaction method and direct DNA sequencing. Results: Rough Collies, Australian Shepherds, Shetland Sheepdogs, and Old English Sheepdogs were affected by the mutation with mutant allelic frequencies of 57.14%, 12.82%, 11.28%, and 8.33%, respectively. Among these populations, the prevalence of the MDR1 (+/–) genotype was 57.14% (12/21) for Rough Collies, 25.64% (10/39) for Australian Shepherds, 16.13% (15/93) for Shetland Sheepdogs, and 16.67% (2/12) for Old English Sheepdogs, whereas the MDR1 (–/–) mutation was only identified in Rough Collies and Shetland Sheepdogs, with prevalences of 28.57% (6/21) and 3.22% (3/93), respectively. However, the MDR1 nt230(del4) was not identified in Border Collies, German Shepherds, White Swiss Shepherds, or Thai Ridgebacks. Conclusion: This study provides the current situation regarding MDR1 nt230(del4) in herding dog breeds in Thailand. In this survey, we investigated for the first time the status of MDR1 genotype in Thai Ridgebacks. These results are helpful for veterinarians managing effective therapeutic plans for commonly affected dog breeds, and these results will encourage all breeders to improve their selective breeding programs based on the MDR1 nt230(del4) status.
Collapse
Affiliation(s)
- Chommanad Lerdkrai
- Department of Physiology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Nuch Phungphosop
- Department of Physiology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
11
|
Orekhova K, Mazzariol S, Sussan B, Bucci M, Bonsembiante F, Verin R, Centelleghe C. Immunohistochemical Markers of Apoptotic and Hypoxic Damage Facilitate Evidence-Based Assessment in Pups with Neurological Disorders. Vet Sci 2021; 8:vetsci8100203. [PMID: 34679033 PMCID: PMC8537515 DOI: 10.3390/vetsci8100203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 09/14/2021] [Accepted: 09/18/2021] [Indexed: 12/15/2022] Open
Abstract
Seizures in puppies often present a diagnostic challenge in terms of identifying and treating the underlying cause. Dog breeds with mutations of the MDR1-gene are known to show adverse reactions to certain drugs, yet metabolic imbalance exacerbated by physiologically immature organs and other contributing pathologies require consideration before arriving at a diagnosis. This study analysed the brains of two male, 5-week-old Australian Shepherd siblings that died after displaying severe neurological symptoms upon administration of MilproVet® to treat severe intestinal helminth infection. Despite the initial symptoms being similar, their case histories varied in terms of the symptom duration, access to supportive therapy and post-mortem interval. Histopathology and immunohistochemistry were used to obtain more information about the phase of the pathological processes in the brain, employing protein markers associated with acute hypoxic damage (β-amyloid precursor protein/APP) and apoptosis (diacylglycerolkinase-ζ/DGK-ζ, apoptotic protease activating factor 1/Apaf1, and B-cell lymphoma related protein 2/Bcl-2). The results seem to reflect the course of the animals' clinical deterioration, implicating that the hypoxic damage to the brains was incompatible with life, and suggesting the usefulness of the mentioned immunohistochemical markers in clarifying the cause of death in animals with acute neurological deficits.
Collapse
Affiliation(s)
- Ksenia Orekhova
- Department of Comparative Biomedicine and Food Science, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (S.M.); (F.B.); (R.V.); (C.C.)
- Correspondence:
| | - Sandro Mazzariol
- Department of Comparative Biomedicine and Food Science, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (S.M.); (F.B.); (R.V.); (C.C.)
| | - Beatrice Sussan
- Department of Animal Medicine, Production and Health, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (B.S.); (M.B.)
| | - Massimo Bucci
- Department of Animal Medicine, Production and Health, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (B.S.); (M.B.)
| | - Federico Bonsembiante
- Department of Comparative Biomedicine and Food Science, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (S.M.); (F.B.); (R.V.); (C.C.)
- Department of Animal Medicine, Production and Health, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (B.S.); (M.B.)
| | - Ranieri Verin
- Department of Comparative Biomedicine and Food Science, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (S.M.); (F.B.); (R.V.); (C.C.)
| | - Cinzia Centelleghe
- Department of Comparative Biomedicine and Food Science, University of Padova AGRIPOLIS, viale dell’Università 16, 35020 Legnaro, Italy; (S.M.); (F.B.); (R.V.); (C.C.)
| |
Collapse
|
12
|
Galindo J, Ayala MA, Sánchez DR, Hernández C, Duifhuis T. Novel genotyping assay for the nt230 (del4) ABCB1 gene mutation and its allele frequency in Border Collie dogs in Mexico. J Vet Diagn Invest 2021; 33:1133-1136. [PMID: 34344235 DOI: 10.1177/10406387211033839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
A 4-bp deletion in the ATP-binding cassette subfamily B member 1 (ABCB1) gene, also referred to as the multidrug resistance gene (MDR1), produces stop codons that cause premature termination of P-glycoprotein 1 (P-gp) synthesis. Dogs with the homozygous mutation do not express functional P-gp, which increases their sensitivity markedly to many common veterinary drugs. We detected the nt230 (del4) ABCB1 mutation in Border Collie dogs in western Mexico with a simple and affordable primer-introduced restriction analysis PCR (PIRA-PCR). PIRA-PCR clearly identified all genotypes in our sample of 104 dogs. Genotype frequencies were 0.952 (wild/wild), 0.029 (wild/mut) and 0.019 (mut/mut). Allele frequencies were 0.033 (mutant alleles) and 0.966 (wild-type alleles). In this small subset of the Mexican dog population, we found a higher prevalence of the nt230 (del4) MDR1/ABCB1 gene mutation than reported in other countries.
Collapse
Affiliation(s)
- Jorge Galindo
- Departamento de Producción Animal, División de Ciencias Veterinarias, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Jalisco, México
| | - Miguel A Ayala
- Departamento de Producción Animal, División de Ciencias Veterinarias, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Jalisco, México
| | - David R Sánchez
- Departamento de Producción Animal, División de Ciencias Veterinarias, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Jalisco, México
| | - Cecilia Hernández
- Departamento de Producción Animal, División de Ciencias Veterinarias, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Jalisco, México
| | - Theodor Duifhuis
- Departamento de Producción Animal, División de Ciencias Veterinarias, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Jalisco, México
| |
Collapse
|
13
|
Abstract
Herding is done predominantly by breeds developed over centuries to millennia specifically for that purpose. Working-level herding breed dogs are intense, high-drive dogs that will work despite severe illness or pain, thereby masking clues that they are ailing or the nature of their problem. The handler should recognize subtle changes that might signal ill health, and veterinarians should take an active role in training handlers on essential skills. Herding dogs typically work entirely outdoors in rural to wilderness environments with continuous exposure to other domestic animals and wildlife and may be affected by trauma, toxin exposure, infectious diseases, and parasitic infections.
Collapse
Affiliation(s)
- Marcella Ridgway
- College of Veterinary Medicine, University of Illinois, Urbana, IL 61802, USA.
| |
Collapse
|
14
|
Guillen A, Smallwood K, Killick DR. Molecular pathology in the cancer clinic - where are we now and where are we headed? J Small Anim Pract 2021; 62:507-520. [PMID: 33974272 DOI: 10.1111/jsap.13330] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 12/14/2020] [Accepted: 03/04/2021] [Indexed: 11/29/2022]
Abstract
Molecular pathology is a developing sub-microscopic discipline of pathology that studies the effects of molecular variations and mutations on disease processes. The ultimate goal of molecular pathology in cancer is to predict risk, facilitate diagnosis and improve prognostication based on a complete understanding of the biological impact of specific molecular variations, mutations and dysregulations. This knowledge will provide the basis for customised cancer treatment, so-called precision medicine. Rapid developments in genomics have placed this field at the forefront of clinical molecular pathology and there are already a number of well-established genetic tests available for clinical use including PCR of antigen receptor rearrangement and KIT mutational analysis. Moving beyond tests assessing a single gene, there are significant research efforts utilising genomics to predict cancer risk, forecast aggressive behaviour and identify druggable mutations and therapeutic biomarkers. Researchers are also investigating the use of circulating cells and nucleic acid for clinically useful low morbidity genomic assessments. If we are to realise the full potential of molecular pathology and precision medicine there are a number of challenges to overcome. These include developing our understanding of the underlying biology (in particular intra-tumoural heterogeneity), methodological standardisation of assays, provision of adequate infrastructure and production of novel therapeutics backed by high-quality clinical data supporting the precision medicine approach. The era of molecular pathology holds the potential to revolutionise veterinary cancer care, but its impact on clinical practice will depend upon the extent to which the inherent challenges can be overcome.
Collapse
Affiliation(s)
- A Guillen
- Department of Clinical Science and Services, Royal Veterinary College, Hawkshead Ln, Hatfield, AL9 7TA, UK
| | - K Smallwood
- Department of Small Animal Clinical Science, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst, Chester High Road, Neston, CH64 7TE, UK
| | - D R Killick
- Department of Small Animal Clinical Science, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst, Chester High Road, Neston, CH64 7TE, UK
| |
Collapse
|
15
|
PREVALENCE OF THE ABCB1-1Δ GENE IN NONDOMESTIC SPECIES OF THE CANIDAE FAMILY. J Zoo Wildl Med 2021; 51:1007-1011. [PMID: 33480582 DOI: 10.1638/2020-0057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/24/2020] [Indexed: 11/21/2022] Open
Abstract
The ABCB1 gene is responsible for encoding the P-glycoprotein (P-gp) efflux transporter that prevents accumulation of exogenous substances in the body by utilizing ATP hydrolysis to transport these substances against their concentration gradient. In dogs, homozygous or heterozygous mutations for the previously described ABCB1-1Δ mutation lead to ineffective P-gp efflux transport function and puts the animal at risk for potentially devastating adverse drug effects. The purpose of this study was to evaluate ABCB1-1Δ gene mutation status in species belonging to the Canidae family, including each of the following: maned wolf (Chrysocyon brachyurus), gray wolf (Canis lupus), red wolf (Canis rufus), coyote (Canis latrans), dingo (Canis lupus dingo), New Guinea singing dog (Canis lupus dingo), arctic fox (Vulpes lagopus), and fennec fox (Vulpes zerda). These species were chosen based on an evolutionary study conducted by Belyaev that noted foxes, bred for temperament, tended to have similar behaviors seen in the modern-day dog. Wolves, known predecessors to the modern dog, were also included. In the current study, a buccal swab was performed on each animal and then tested at Washington State University's Veterinary Clinical Pharmacology Lab, where they were tested according to previously published methods validating buccal swab samples and polymerase chain reaction (PCR) -based genetic analysis. Knowledge of Canidae species ABCB1-1Δ gene mutation status allows for safe and effective therapeutic treatment of nondomestic animals, ensuring any anticipated adverse drug events are prevented. All eight species were found to have the wild-type ABCB1 gene and thus, expected to have normally functioning P-gp efflux transporters. Although these data can be used to guide clinical decision making, because of a small sample size, a more robust study is necessary to assess Canidae ABCB1-1Δ mutation status comprehensively.
Collapse
|
16
|
LaQuaglia KA, Robertson JB, Lunn KF. Neutropenia in dogs receiving vincristine for treatment of presumptive immune-mediated thrombocytopenia. J Vet Intern Med 2021; 35:226-233. [PMID: 33421218 PMCID: PMC7848356 DOI: 10.1111/jvim.16029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 12/17/2020] [Accepted: 12/18/2020] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Neutropenia is an adverse effect of vincristine when used in multidrug chemotherapy protocols. OBJECTIVE To determine the incidence of neutropenia, identify potential risk factors for neutropenia, and determine the effect of neutropenia on outcome, in dogs receiving vincristine for treatment of immune-mediated thrombocytopenia (ITP). ANIMALS One hundred twenty-seven client-owned dogs presumptively diagnosed with ITP. METHODS In this retrospective cohort study, medical records were reviewed to identify dogs presumptively diagnosed with ITP, and treated with vincristine, over a 15-year period. Logistic regression was used to identify risk factors for the development of neutropenia in dogs receiving vincristine. Time to platelet count ≥40 000 platelets/μL, survival, and duration of hospitalization were compared between neutropenic and non-neutropenic dogs. RESULTS Vincristine was administered to 127 dogs with presumptive ITP; 19 became neutropenic. Administration of cyclosporine was significantly (P < .001) associated with the development of neutropenia (odds ratio: 12.97, 95% confidence interval: 4.17, 40.35). There was no difference in median time to ≥40 000 platelets/μL between neutropenic dogs (4 days; range, 1-14 days) and non-neutropenic dogs (3 days; range, 0-48 days). Percentage survival to discharge was 95% in both groups, but median duration of hospitalization was significantly longer in neutropenic dogs (6 days; range, 3-22 days) compared to non-neutropenic dogs (4 days; range, 2-15 days). CONCLUSIONS AND CLINICAL IMPORTANCE Cyclosporine administration was associated with the development of neutropenia in dogs receiving vincristine, which might be related to effects on metabolism of vincristine. Neutrophil counts should be monitored in dogs receiving vincristine treatment for ITP, particularly if administered in conjunction with cyclosporine.
Collapse
Affiliation(s)
- Kathryn A LaQuaglia
- Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina, USA
| | - James B Robertson
- College of Veterinary Medicine, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, USA
| | - Katharine F Lunn
- Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina, USA
| |
Collapse
|
17
|
Marcum BA, Li Z, Turek JJ, Moore GE, Nolte DD, Childress MO. Biodynamic signatures from ex vivo bone marrow aspirates are associated with chemotherapy-induced neutropenia in cancer-bearing dogs. Vet Med Sci 2020; 7:665-673. [PMID: 33369129 PMCID: PMC8136957 DOI: 10.1002/vms3.423] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 11/18/2020] [Accepted: 12/09/2020] [Indexed: 12/27/2022] Open
Abstract
Background Neutropenia is the most common dose‐limiting side effect of cytotoxic chemotherapy in cancer‐bearing dogs. Biodynamic imaging (BDI) is a functional imaging technology that measures dynamic light scattering from living, three‐dimensional tissues to characterize intracellular motion within those tissues. Previous studies have associated BDI biomarkers with tumour sensitivity to chemotherapy agents in dogs with naturally occurring cancer. We hypothesized that BDI, performed ex vivo on bone marrow aspirate samples, would identify dynamic biomarkers associated with the occurrence of specific degrees of neutropenia in tumour‐bearing dogs receiving doxorubicin chemotherapy. Materials and Methods Bone marrow aspirates were collected from 10 dogs with naturally occurring cancers prior to initiation of doxorubicin treatment. BDI was performed on bone marrow samples treated ex vivo with doxorubicin at 0.1, 1, 10 and 100 μM along with 0.1% DMSO as a control. Dogs then were treated with doxorubicin (30 mg/m2, intravenously). Peripheral blood neutrophil counts were obtained on the day of treatment and again 7 days later. Receiver operating characteristic curves identified provisional breakpoints for BDI biomarkers that correlated with specific changes in neutrophil counts between the two time points. Results Provisional breakpoints for several BDI biomarkers were identified, specifying dogs with the largest proportionate change in neutrophils and with neutropenia that was grade 2 or higher following doxorubicin treatment. Conclusions Biodynamic imaging of bone marrow aspirates may identify those dogs at greater risk for neutropenia following doxorubicin chemotherapy. This approach may be useful for pre‐emptively modifying chemotherapy dosing in dogs to avoid unacceptable side effects.
Collapse
Affiliation(s)
- Blake A Marcum
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| | - Zhe Li
- Department of Physics and Astronomy, College of Science, Purdue University, West Lafayette, IN, USA
| | - John J Turek
- Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| | - George E Moore
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| | - David D Nolte
- Department of Physics and Astronomy, College of Science, Purdue University, West Lafayette, IN, USA
| | - Michael O Childress
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| |
Collapse
|
18
|
Mueller RS, Rosenkrantz W, Bensignor E, Karaś-Tęcza J, Paterson T, Shipstone MA. Diagnosis and treatment of demodicosis in dogs and cats: Clinical consensus guidelines of the World Association for Veterinary Dermatology. Vet Dermatol 2020; 31:5-27. [PMID: 31957202 DOI: 10.1111/vde.12806] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2019] [Indexed: 12/01/2022]
Abstract
BACKGROUND Demodicosis is a common disease in small animal veterinary practice worldwide with a variety of diagnostic and therapeutic options. OBJECTIVES To provide consensus recommendations on the diagnosis, prevention and treatment of demodicosis in dogs and cats. METHODS AND MATERIALS The authors served as a Guideline Panel (GP) and reviewed the literature available before December 2018. The GP prepared a detailed literature review and made recommendations on selected topics. A draft of the document was presented at the North American Veterinary Dermatology Forum in Maui, HI, USA (May 2018) and at the European Veterinary Dermatology Congress in Dubrovnik, Croatia (September 2018) and was made available via the World Wide Web to the member organizations of the World Association for Veterinary Dermatology for a period of three months. Comments were solicited and responses were incorporated into the final document. CONCLUSIONS In young dogs with generalized demodicosis, genetic and immunological factors seem to play a role in the pathogenesis and affected dogs should not be bred. In old dogs and cats, underlying immunosuppressive conditions contributing to demodicosis should be explored. Deep skin scrapings are the diagnostic gold standard for demodicosis, but trichograms and tape squeeze preparations may also be useful under certain circumstances. Amitraz, macrocyclic lactones and more recently isoxazolines have all demonstrated good efficacy in the treatment of canine demodicosis. Therapeutic selection should be guided by local drug legislation, drug availability and individual case parameters. Evidence for successful treatment of feline demodicosis is strongest for lime sulfur dips and amitraz baths.
Collapse
Affiliation(s)
- Ralf S Mueller
- Centre for Clinical Veterinary Medicine, LMU Munich, Veterinaerstraße 13, 80539, Munich, Germany
| | | | - Emmanuel Bensignor
- Dermatology Referral Service, 75003, Paris, 35510 Cesson-Sévigné, and 44000, Nantes, France
| | - Joanna Karaś-Tęcza
- Dermawet Dermatology Service for Dogs and Cats, Odyńca 37 lok.1/2, 02-606, Warszawa, Poland
| | - Tara Paterson
- Small Animal Medicine & Surgery Department, School of Veterinary Medicine, St. George's University, PO Box #7, St George's, Grenada, West Indies
| | - Michael A Shipstone
- Dermatology for Animals, 263 Appleby Road, Stafford Heights, Brisbane, Queensland, 4053, Australia
| |
Collapse
|
19
|
El-Saber Batiha G, Alqahtani A, Ilesanmi OB, Saati AA, El-Mleeh A, Hetta HF, Magdy Beshbishy A. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. Pharmaceuticals (Basel) 2020; 13:E196. [PMID: 32824399 PMCID: PMC7464486 DOI: 10.3390/ph13080196] [Citation(s) in RCA: 81] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Revised: 08/09/2020] [Accepted: 08/13/2020] [Indexed: 12/15/2022] Open
Abstract
Avermectins are a group of drugs that occurs naturally as a product of fermenting Streptomyces avermitilis, an actinomycetes, isolated from the soil. Eight different structures, including ivermectin, abamectin, doramectin, eprinomectin, moxidectin, and selamectin, were isolated and divided into four major components (A1a, A2a, B1a and B2a) and four minor components (A1b, A2b, B1b, and B2b). Avermectins are generally used as a pesticide for the treatment of pests and parasitic worms as a result of their anthelmintic and insecticidal properties. Additionally, they possess anticancer, anti-diabetic, antiviral, antifungal, and are used for treatment of several metabolic disorders. Avermectin generally works by preventing the transmission of electrical impulse in the muscle and nerves of invertebrates, by amplifying the glutamate effects on the invertebrates-specific gated chloride channel. Avermectin has unwanted effects or reactions, especially when administered indiscriminately, which include respiratory failure, hypotension, and coma. The current review examines the mechanism of actions, biosynthesis, safety, pharmacokinetics, biological toxicity and activities of avermectins.
Collapse
Affiliation(s)
- Gaber El-Saber Batiha
- Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Egypt
| | - Ali Alqahtani
- Department of Pharmacology, College of Pharmacy, King Khalid University, Guraiger, Abha 62529, Saudi Arabia;
| | - Omotayo B. Ilesanmi
- Department of Biochemistry, Faculty of Science, Federal University Otuoke, Otuoke 561, Nigeria;
| | - Abdullah A. Saati
- Department of Community Medicine & Pilgrims Healthcare, Faculty of Medicine, Umm Al-Qura University Makkah, Mecca 24382, Saudi Arabia;
| | - Amany El-Mleeh
- Department of Pharmacology, Faculty of Veterinary Medicine, Menoufia University, Shibin Al Kawm 32511, Egypt;
| | - Helal F. Hetta
- Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt;
- Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45221, USA
| | - Amany Magdy Beshbishy
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Nishi 2-13, Inada-cho, Obihiro 080-8555, Hokkaido, Japan
| |
Collapse
|
20
|
Marelli SP, Polli M, Frattini S, Cortellari M, Rizzi R, Crepaldi P. Genotypic and allelic frequencies of MDR1 gene in dogs in Italy. Vet Rec Open 2020; 7:e000375. [PMID: 32617164 PMCID: PMC7319724 DOI: 10.1136/vetreco-2019-000375] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 02/18/2020] [Accepted: 03/05/2020] [Indexed: 12/28/2022] Open
Abstract
Background A mutation in the canine multidrug resistance MDR1 gene (also referred as ABCB1), encoding for the multidrug resistance (MDR) P-glycoprotein (P-gp) transponder, causes a pathological condition known as ‘ivermectin toxicosis’. The causative mutation, known since 2001, has been described to affects sheep herding breeds related to collie lineage. The present study is a retrospective investigation of the presence of MDR1 mutated allele in Italian dog populations in a 5 years’ time lapse. The aim of the research is to offer a deep knowledge in MDR1 allelic and genotypic frequencies in canine breeds and populations raised in Italy. Methods Genotype data for the 4-bp deletion (c296_299del4) in MDR1 gene from 811 dogs belonging to 32 breeds/populations were collected. Results The mutated allele has been found in 9 out of 31 breeds: Rough Collie, Smooth Collie, Border Collie, Bearded Collie, Shetland Sheepdog, Australian Shepherd, White Swiss Shepherd, Old English Sheepdog, Whippet and also in crossbreed. The breeds with the highest allelic mutation frequency are Smooth and Rough Collies with 75 per cent and 66 per cent of mutant MDR1 allele, respectively. Conclusions The results support the usefulness of this genetic analysis to optimise medical care in dogs at risk of multidrug resistance and to create an objective basis in breeding programme definition and in the risk evaluation in different breeds.
Collapse
Affiliation(s)
- Stefano Paolo Marelli
- Department of Veterinary Medicine, Università degli Studi di Milano, Milano, Lombardia, Italy
| | - Michele Polli
- Department of Veterinary Medicine, Università degli Studi di Milano, Milano, Lombardia, Italy
| | - Stefano Frattini
- Department of Agricultural and Environmental Sciences-Production, Landscape, Agroenergy, Università degli Studi di Milano, Milano, Lombardia, Italy
| | - Matteo Cortellari
- Department of Agricultural and Environmental Sciences-Production, Landscape, Agroenergy, Università degli Studi di Milano, Milano, Lombardia, Italy
| | - Rita Rizzi
- Department of Veterinary Medicine, Università degli Studi di Milano, Milano, Lombardia, Italy
| | - Paola Crepaldi
- Department of Agricultural and Environmental Sciences-Production, Landscape, Agroenergy, Università degli Studi di Milano, Milano, Lombardia, Italy
| |
Collapse
|
21
|
Silvestro CA, Soria LA, Conte A, Marrube G. Two methods for genotyping a 4-base deletion in the canine ABCB1 gene. J Vet Diagn Invest 2020; 31:889-892. [PMID: 31711409 DOI: 10.1177/1040638719887374] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
A 4-bp deletion (c.230_233delATAG) of the ABCB1 gene, frequently found in various dog breeds, results in intolerance to certain drugs routinely used in veterinary medicine, including many chemotherapeutic agents and macrocyclic lactones. The use of rapid and reliable genetic testing is fundamental for early detection of the mutation and prevention of undesirable toxicoses. We developed and compared 2 genotyping tests: PCR-high-resolution melting (PCR-HRM) and PCR-restriction-fragment length polymorphism (PCR-RFLP) to identify the 4-bp deletion in the ABCB1 gene of canine breeds. Amplified PCR products were sequenced in order to confirm different genotypes. Both techniques were efficient in discriminating homozygous wild-type, homozygous mutated, and heterozygous ABCB1 genotypes, and proved to be reproducible and economical methods. The HRM analysis, a sensitive and specific method for the molecular detection of genetic disorders, does not require labeled probes, processing, or separations after PCR.
Collapse
Affiliation(s)
- Carolina A Silvestro
- Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Genética, Buenos Aires, Argentina
| | - Liliana A Soria
- Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Genética, Buenos Aires, Argentina
| | - Adriana Conte
- Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Genética, Buenos Aires, Argentina
| | - Graciela Marrube
- Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Genética, Buenos Aires, Argentina
| |
Collapse
|
22
|
Soussa RW, Woodward A, Marty M, Cannon CM. Breed is associated with the ABCB1-1Δ mutation in Australian dogs. Aust Vet J 2019; 98:79-83. [PMID: 31743433 DOI: 10.1111/avj.12896] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Revised: 10/18/2019] [Accepted: 10/29/2019] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The ABCB1 gene encodes P-glycoprotein (P-gp), a cellular membrane pump. One functional mutation that leads to expression of a less functional form of P-gp, ABCB1-1Δ, has been described in dogs. Individuals with this mutation can have severe adverse reactions to common veterinary pharmaceuticals that are known substrates of this pump. We investigated the detection of this mutation in samples submitted to two Australian diagnostic laboratories. METHODS A total of 4842 dogs across 27 breeds were tested for the ABCB1-1Δ mutation from buccal swabs or EDTA blood using standard PCR, multiplex PCR, or genotyping chip. Statistical analysis was applied to determine the proportions and odds ratios of the ABCB1-1Δ mutation in herding breeds compared with non-herding breeds. RESULTS The ABCB1-1Δ mutation was detected in nine breeds. The most commonly affected breeds were collies, Australian shepherds, white Swiss shepherds, and Shetland sheepdogs. Of 32 dogs in 18 non-herding breeds tested, one cocker spaniel and one labradoodle were positive for the mutation, both heterozygous. CONCLUSION The most frequently affected breeds for ABCB1-1Δ mutation are the collie, Australian shepherd, white Swiss shepherd and Shetland sheepdog. As the mutation is associated with an increased incidence of adverse reactions to commonly used pharmaceuticals, veterinarians need to be aware of the breeds at most risk of carrying this mutation and consider testing these individuals prior to administering these medications.
Collapse
Affiliation(s)
- R W Soussa
- Internal Medicine Department, Southpaws Specialty Surgery for Animals, Moorabbin, Victoria, 3189, Australia
| | - A Woodward
- Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, Victoria, 3030, Australia
| | - M Marty
- Genetic Testing Division, Genomic Diagnostics, Heidelberg, Victoria, 3084, Australia
| | - C M Cannon
- Department of Veterinary Clinical Sciences, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, 3030, Australia
| |
Collapse
|
23
|
Ozdemir Z, Faki HE, Uney K, Tras B. Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. J Vet Pharmacol Ther 2019; 42:497-504. [PMID: 31183888 DOI: 10.1111/jvp.12769] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 03/22/2019] [Accepted: 03/25/2019] [Indexed: 12/28/2022]
Abstract
The purpose of this study was to determine the pharmacokinetic interaction between ivermectin (0.4 mg/kg) and praziquantel (10 mg/kg) administered either alone or co-administered to dogs after oral treatment. Twelve healthy cross-bred dogs (weighing 18-21 kg, aged 1-3 years) were allocated randomly into two groups of six dogs (four females, two males) each. In first group, the tablet forms of praziquantel and ivermectin were administered using a crossover design with a 15-day washout period, respectively. Second group received tablet form of ivermectin plus praziquantel. The plasma concentrations of ivermectin and praziquantel were determined by high-performance liquid chromatography using a fluorescence and ultraviolet detector, respectively. The pharmacokinetic parameters of ivermectin following oral alone-administration were as follows: elimination half-life (t1/2λz ) 110 ± 11.06 hr, area under the plasma concentration-time curve (AUC0-∞ ) 7,805 ± 1,768 hr. ng/ml, maximum concentration (Cmax ) 137 ± 48.09 ng/ml, and time to reach Cmax (Tmax ) 14.0 ± 4.90 hr. The pharmacokinetic parameters of praziquantel following oral alone-administration were as follows: t1/2λz 7.39 ± 3.86 hr, AUC0-∞ 4,301 ± 1,253 hr. ng/ml, Cmax 897 ± 245 ng/ml, and Tmax 5.33 ± 0.82 hr. The pharmacokinetics of ivermectin and praziquantel were not changed, except Tmax of praziquantel in the combined group. In conclusion, the combined formulation of ivermectin and praziquantel can be preferred in the treatment and prevention of diseases caused by susceptible parasites in dogs because no pharmacokinetic interaction was determined between them.
Collapse
Affiliation(s)
- Zeynep Ozdemir
- Anatolia Medicine & Chemical Industry Corporation, Konya, Turkey
| | - Hatice Eser Faki
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Selcuk, Konya, Turkey
| | - Kamil Uney
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Selcuk, Konya, Turkey
| | - Bunyamin Tras
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Selcuk, Konya, Turkey
| |
Collapse
|
24
|
Mealey KL, Martinez SE, Villarino NF, Court MH. Personalized medicine: going to the dogs? Hum Genet 2019; 138:467-481. [PMID: 31032534 DOI: 10.1007/s00439-019-02020-w] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Accepted: 04/19/2019] [Indexed: 12/13/2022]
Abstract
Interindividual variation in drug response occurs in canine patients just as it does in human patients. Although canine pharmacogenetics still lags behind human pharmacogenetics, significant life-saving discoveries in the field have been made over the last 20 years, but much remains to be done. This article summarizes the available published data about the presence and impact of genetic polymorphisms on canine drug transporters, drug-metabolizing enzymes, drug receptors/targets, and plasma protein binding while comparing them to their human counterparts when applicable. In addition, precision medicine in cancer treatment as an application of canine pharmacogenetics and pertinent considerations for canine pharmacogenetics testing is reviewed. The field is poised to transition from single pharmacogene-based studies, pharmacogenetics, to pharmacogenomic-based studies to enhance our understanding of interindividual variation of drug response in dogs. Advances made in the field of canine pharmacogenetics will not only improve the health and well-being of dogs and dog breeds, but may provide insight into individual drug efficacy and toxicity in human patients as well.
Collapse
Affiliation(s)
- Katrina L Mealey
- Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA, 99163, USA.
| | - Stephanie E Martinez
- Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA, 99163, USA
| | - Nicolas F Villarino
- Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA, 99163, USA
| | - Michael H Court
- Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA, 99163, USA
| |
Collapse
|
25
|
Dowling M, Samuelson J, Fadl-Alla B, Pondenis HC, Byrum M, Barger AM, Fan TM. Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions. PLoS One 2019; 14:e0210297. [PMID: 30601866 PMCID: PMC6314605 DOI: 10.1371/journal.pone.0210297] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Accepted: 12/18/2018] [Indexed: 12/22/2022] Open
Abstract
Background Canine hemangiosarcoma (cHSA) is a highly metastatic mesenchymal cancer that disseminates by hematogenous and direct implantation routes. Therapies for cHSA are generally ineffective, in part due to advanced clinical disease stage at the time of diagnosis. The validation of conventional molecular methods for detecting novel biomarkers preferentially expressed by cHSA could lead to more timely diagnosis, earlier therapeutic interventions, and improved outcomes. In humans, prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed by prostate carcinoma and tumor-associated endothelium of various solid cancer histologies. Importantly, the preferential overexpression of PSMA by certain cancers has been leveraged for the development of diagnostic molecular imaging reagents and targeted therapeutics. Recently, PSMA has been qualitatively demonstrated to be expressed in cHSA cell lines, however, quantitative PSMA expressions and the potential utility of PSMA transcript identification in biologic fluids to support the presence of microscopic cHSA burden has not been reported. Therefore, this study sought to characterize the differential quantitative expressions of PSMA between cHSA and non-malignant tissues, and to determine the potential diagnostic utility of PCR-generated PSMA amplicons as a surrogate of rare cHSA cells dwelling within peritoneal and pericardial cavities. Methods Quantitative gene and protein expressions for PSMA were compared between one normal endothelial and six cHSA cell lines by RT-PCR, western blot analysis, and fluorescent microscopy. Additionally, gene and protein expressions of PSMA in normal canine tissues were characterized. Graded expressions of PSMA were determined in spontaneously-arising cHSA tumor samples and the feasibility of qualitative PCR as a molecular diagnostic to detect PSMA transcripts in whole blood from healthy dogs and hemorrhagic effusions from cHSA-bearing dogs were evaluated. Results PSMA gene and protein expressions were elevated (up to 6-fold) in cHSA cells compared with non-malignant endothelium. By immunohistochemistry, protein expressions of PSMA were detectable in all cHSA tissue samples evaluated. As predicted by human protein atlas data, PSMA’s expression was comparably identified at substantial levels in select normal canine tissues including kidney, liver, and intestine. In young healthy pet dogs, PSMA amplicons could not be identified in circulating whole blood yet were detectable in hemorrhagic effusions collected from pet dogs with confirmed cHSA or PSMA-expressing cancer. Conclusions PSMA is quantitatively overexpressed in cHSA compared to normal endothelium, but its protein expression is not restricted to only cHSA tumor tissues, as specific visceral organs also substantively express PSMA. Optimized qualitative PCR methods failed to amplify PSMA amplicons sufficiently for visible detection in circulating whole blood derived from healthy young dogs, yet PSMA transcripts were readily identifiable in hemorrhagic effusions collected from pet dogs with histologically confirmed cHSA or PSMA-expressing cancer. While preliminary, findings derived from a limited cohort of normal and diseased pet dogs provocatively raise the potential value of PSMA amplicon detection as an ancillary molecular diagnostic test for supporting the presence of microscopic cHSA disease burden within hemorrhagic body cavity effusions.
Collapse
Affiliation(s)
- Matthew Dowling
- Department of Veterinary Clinical Medicine, University of Illinois, Urbana, IL, United States of America
| | - Jonathan Samuelson
- Department of Pathobiology, University of Illinois, Urbana, IL, United States of America
| | - Bahaa Fadl-Alla
- Department of Pathobiology, University of Illinois, Urbana, IL, United States of America
| | - Holly C. Pondenis
- Department of Veterinary Clinical Medicine, University of Illinois, Urbana, IL, United States of America
| | - Mark Byrum
- Department of Veterinary Clinical Medicine, University of Illinois, Urbana, IL, United States of America
| | - Anne M. Barger
- Department of Veterinary Clinical Medicine, University of Illinois, Urbana, IL, United States of America
| | - Timothy M. Fan
- Department of Veterinary Clinical Medicine, University of Illinois, Urbana, IL, United States of America
- * E-mail:
| |
Collapse
|
26
|
Toxicology of Avermectins and Milbemycins (Macrocyclic Lactones) and the Role of P-Glycoprotein in Dogs and Cats. Vet Clin North Am Small Anim Pract 2018; 48:991-1012. [PMID: 30139545 DOI: 10.1016/j.cvsm.2018.07.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Overdoses of macrocyclic lactones in dogs and cats can result in such signs as tremors, ataxia, seizures, coma, and blindness. Dogs with the ABCB1-1Δ gene defect are predisposed to macrocyclic lactone toxicosis at lower dosages than dogs without the defect. Intravenous lipid emulsion therapy has been suggested for treatment of macrocyclic lactone toxicosis but evidence of efficacy is limited. Initial decontamination and supportive care remain the mainstays of therapy for macrocyclic lactone toxicosis.
Collapse
|
27
|
Harding K, Bergman N, Smith A, Lindley S, Szivek A, Milner R, Brawner W, Lejeune A. Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma. Vet Comp Oncol 2018; 16:636-641. [PMID: 30117260 DOI: 10.1111/vco.12433] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Revised: 07/11/2018] [Accepted: 07/12/2018] [Indexed: 12/12/2022]
Abstract
Vincristine is included in vincristine, cyclophosphamide, doxorubicin and prednisone (CHOP) chemotherapy protocols, which are the gold-standard treatment for high-grade canine lymphoma. Vincristine can result in relatively high rates of gastrointestinal toxicity, whereas vinblastine is generally well tolerated and thus may represent an under-utilized and minimally toxic alternative to vincristine. Our objective was to determine the response rate and toxicity associated with a single dose of vinblastine administered to dogs with treatment-naïve, intermediate to large-cell, multicentric lymphoma. Twenty client-owned dogs were enrolled with signed owner consent. A Simon's minimax, phase II, two-stage trial was performed to test the efficacy of vinblastine administered at 2 mg/m2 IV followed by a pilot trial of vinblastine at 2.5 mg/m2 . No dogs were administered concurrent steroids or other chemotherapy. One out of 14 dogs receiving vinblastine at 2 mg/m2 demonstrated a partial response. Three out of five dogs demonstrated a partial response to vinblastine at 2.5 mg/m2 . Gastrointestinal toxicity was infrequent and low grade for both groups. The majority of dogs (80%) in the 2.5 mg/m2 dosing group developed neutropenia 1-week post administration. Vinblastine was well tolerated but minimally efficacious at a dose of 2 mg/m2 IV in dogs with treatment-naive, multicentric lymphoma. Because of poor response rates, treatment at this dose is not recommended. A small subset of dogs administered 2.5 mg/m2 had significantly improved response rates (P = 0.04), suggesting that higher doses may have improved efficacy, although further research is indicated to confirm these preliminary findings.
Collapse
Affiliation(s)
- K Harding
- University of Florida Small Animal Hospital, Gainesville, Florida
| | - N Bergman
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - A Smith
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - S Lindley
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - A Szivek
- University of Florida Small Animal Hospital, Gainesville, Florida
| | - R Milner
- University of Florida Small Animal Hospital, Gainesville, Florida
| | - W Brawner
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - A Lejeune
- University of Florida Small Animal Hospital, Gainesville, Florida
| |
Collapse
|
28
|
Martinez MN, Court MH, Fink-Gremmels J, Mealey KL. Population variability in animal health: Influence on dose-exposure-response relationships: Part I: Drug metabolism and transporter systems. J Vet Pharmacol Ther 2018; 41:E57-E67. [PMID: 29917248 DOI: 10.1111/jvp.12670] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 04/26/2018] [Accepted: 05/07/2018] [Indexed: 01/03/2023]
Abstract
There is an increasing effort to understand the many sources of population variability that can influence drug absorption, metabolism, disposition, and clearance in veterinary species. This growing interest reflects the recognition that this diversity can influence dose-exposure-response relationships and can affect the drug residues present in the edible tissues of food-producing animals. To appreciate the pharmacokinetic diversity that may exist across a population of potential drug product recipients, both endogenous and exogenous variables need to be considered. The American Academy of Veterinary Pharmacology and Therapeutics hosted a 1-day session during the 2017 Biennial meeting to explore the sources of population variability recognized to impact veterinary medicine. The following review highlights the information shared during that session. In Part I of this workshop report, we consider sources of population variability associated with drug metabolism and membrane transport. Part II of this report highlights the use of modeling and simulation to support an appreciation of the variability in dose-exposure-response relationships.
Collapse
Affiliation(s)
- Marilyn N Martinez
- Center for Veterinary Medicine, US Food and Drug Administration, Rockville, Maryland
| | - Michael H Court
- Program in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington
| | - Johanna Fink-Gremmels
- Division of Pharmacology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
| | - Katrina L Mealey
- Program in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington
| |
Collapse
|
29
|
Bisson JL, Argyle DJ, Argyle SA. Antibiotic prophylaxis in veterinary cancer chemotherapy: A review and recommendations. Vet Comp Oncol 2018; 16:301-310. [PMID: 29892997 DOI: 10.1111/vco.12406] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 03/21/2018] [Accepted: 04/29/2018] [Indexed: 12/22/2022]
Abstract
Bacterial infection following cancer chemotherapy-induced neutropenia is a serious cause of morbidity and mortality in human and veterinary patients. Antimicrobial prophylaxis is controversial in the human oncology field, as any decreased incidence in bacterial infections is countered by patient adverse effects and increased antimicrobial resistance. Comprehensive guidelines exist to aid human oncologists in prescribing antimicrobial prophylaxis but similar recommendations are not available in veterinary literature. As the veterinarian's role in antimicrobial stewardship is increasingly emphasized, it is vital that veterinary oncologists implement appropriate antimicrobial use. By considering the available human and veterinary literature we present an overview of current clinical practices and are able to suggest recommendations for prophylactic antimicrobial use in veterinary cancer chemotherapy patients.
Collapse
Affiliation(s)
- J L Bisson
- The Royal (Dick) School of Veterinary Studies and the Roslin Insitute, University of Edinburgh, Edinburgh, UK
| | - D J Argyle
- The Royal (Dick) School of Veterinary Studies and the Roslin Insitute, University of Edinburgh, Edinburgh, UK
| | - S A Argyle
- The Royal (Dick) School of Veterinary Studies and the Roslin Insitute, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
30
|
Richardson D, Poirier VJ, Matsuyama A, Calvalido J. Correlation Between Body Weight and Mitoxantrone-Associated Neutropenia in Dogs. J Am Anim Hosp Assoc 2018; 54:144-149. [DOI: 10.5326/jaaha-ms-6545] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
ABSTRACT
Thirty-seven dogs with histologically or cytologically confirmed malignant tumors treated with single-agent mitoxantrone at 5 mg/m2 were evaluated in a retrospective study assessing the correlation between body weight and neutropenia associated with a single dose of mitoxantrone in dogs. Overall, eight dogs (21%) experienced grade 3 neutropenia and five dogs (14%) experienced grade 4 neutropenia on day 7 following mitoxantrone chemotherapy. Dogs ≤10 kg body weight were significantly more likely to develop grade 3 or 4 neutropenia (5.8 relative risk; 95% confidence interval, 2.6–12.9; P < .0001) than dogs >10 kg. Dogs ≤15 kg body weight were significantly more likely to develop grade 3 or 4 neutropenia (8.1 relative risk; 95% confidence interval, 2.1–31.3; P < .0001) than dogs >15 kg. Of the 13 patients who developed grade 3 or 4 neutropenia, 6 (46%) were hospitalized for clinical signs related to neutropenia. Based on the severity of neutropenia and the resulting hospitalization seen in dogs ≤10 kg, a dose reduction could be considered for the initial dose of mitoxantrone, and clinicians should be aware of the increased risk of neutropenia in patients 10.1 to ≤15 kg.
Collapse
Affiliation(s)
- Danielle Richardson
- From the Ontario Veterinary College Health Sciences Centre, University of Guelph, Guelph, Ontario, Canada (D.R., A.M., J.C.); and School of Veterinary Science, Massey University, Palmerston North, New Zealand (V.J.P.)
| | - Valerie J. Poirier
- From the Ontario Veterinary College Health Sciences Centre, University of Guelph, Guelph, Ontario, Canada (D.R., A.M., J.C.); and School of Veterinary Science, Massey University, Palmerston North, New Zealand (V.J.P.)
| | - Arata Matsuyama
- From the Ontario Veterinary College Health Sciences Centre, University of Guelph, Guelph, Ontario, Canada (D.R., A.M., J.C.); and School of Veterinary Science, Massey University, Palmerston North, New Zealand (V.J.P.)
| | - Jerome Calvalido
- From the Ontario Veterinary College Health Sciences Centre, University of Guelph, Guelph, Ontario, Canada (D.R., A.M., J.C.); and School of Veterinary Science, Massey University, Palmerston North, New Zealand (V.J.P.)
| |
Collapse
|
31
|
Parker HG, Dreger DL, Rimbault M, Davis BW, Mullen AB, Carpintero-Ramirez G, Ostrander EA. Genomic Analyses Reveal the Influence of Geographic Origin, Migration, and Hybridization on Modern Dog Breed Development. Cell Rep 2018; 19:697-708. [PMID: 28445722 DOI: 10.1016/j.celrep.2017.03.079] [Citation(s) in RCA: 211] [Impact Index Per Article: 35.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Revised: 02/10/2017] [Accepted: 03/28/2017] [Indexed: 11/30/2022] Open
Abstract
There are nearly 400 modern domestic dog breeds with a unique histories and genetic profiles. To track the genetic signatures of breed development, we have assembled the most diverse dataset of dog breeds, reflecting their extensive phenotypic variation and heritage. Combining genetic distance, migration, and genome-wide haplotype sharing analyses, we uncover geographic patterns of development and independent origins of common traits. Our analyses reveal the hybrid history of breeds and elucidate the effects of immigration, revealing for the first time a suggestion of New World dog within some modern breeds. Finally, we used cladistics and haplotype sharing to show that some common traits have arisen more than once in the history of the dog. These analyses characterize the complexities of breed development, resolving longstanding questions regarding individual breed origination, the effect of migration on geographically distinct breeds, and, by inference, transfer of trait and disease alleles among dog breeds.
Collapse
Affiliation(s)
- Heidi G Parker
- Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Dayna L Dreger
- Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Maud Rimbault
- Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Brian W Davis
- Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Alexandra B Mullen
- Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Gretchen Carpintero-Ramirez
- Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Elaine A Ostrander
- Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
| |
Collapse
|
32
|
Dekel Y, Machluf Y, Stoler A, Aderet A, Baumel D, Kellerman E, Plotsky Y, Noked Partouche O, Elhalal G, Ben-Shlomo I, Bercovich D. Frequency of canine nt230(del4) MDR1 mutation in prone pure breeds, their crosses and mongrels in Israel - insights from a worldwide comparative perspective. BMC Vet Res 2017; 13:333. [PMID: 29132368 PMCID: PMC5683241 DOI: 10.1186/s12917-017-1251-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2017] [Accepted: 10/31/2017] [Indexed: 11/25/2022] Open
Abstract
Background Sensitivity to macrocyclic lactones, which are commonly used in veterinary clinics, was first found in Rough Collies, and was attributed in 2001 to a 4 bp deletion in the MDR1 gene. The list of affected breeds currently includes 13 breeds. Researchers from different countries and continents examined the allelic frequencies of the nt230(del4) MDR1 mutation, emphasizing the clinical importance of this test not only to mutation-prone dogs, but also to their crosses and mongrels, since treatment of a deletion carrier with these compounds may lead to its death. In this study, the allelic frequencies of nt230(del4) MDR1 mutation in affected breeds, their crosses, unrelated pure breeds and mongrels are reported for the state of Israel (n = 1416 dogs). The Israeli data were compared with reports from the US, Europe, UK, Australia and Japan. Results The allelic frequencies of nt230(del4) MDR1 mutation in Israel for Australian, Swiss and German Shepherds (31%, 17% and 2.4%, respectively) are similar to the corresponding frequencies worldwide, much higher for Border Collies (4.8%), twice lower for Rough Collies (28%, compared to 55% or more elsewhere), and ~1% for mongrels. The frequencies for crosses of Australian Shepherd and Border Collies in Israel are 4 and 1.6 times lower, respectively, compared to the frequencies for the respective pure breeds. Conclusions This work, that for the first time presents the frequency of nt230(del4) MDR1 mutation in Israel, along with a worldwide survey, has implications for clinicians, owners and breeders of sheepdogs and their crosses and supports the need for extra care in treatment and in future breeding. Of note, the relative proportion of affected breeds, in the overall tested dogs, might be higher than their actual proportion in Israel due to directed samples collection by veterinarians for clinical purposes, as these are mainly limited to certain affected breeds or dogs that resemble them. Electronic supplementary material The online version of this article (10.1186/s12917-017-1251-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yaron Dekel
- Shamir Research Institute, University of Haifa, P.O.Box 97, 1290000, Kazerin, Israel. .,Zefat Academic College, Zefat, Israel. .,GGA - Galil Genetic Analysis Ltd, P.O.Box 3664, 12900, Kazerin, Israel.
| | - Yossy Machluf
- Specialist in the Fields of Genetics, Epidemiology and Molecular Biology, Rehovot, Israel
| | - Aviad Stoler
- GGA - Galil Genetic Analysis Ltd, P.O.Box 3664, 12900, Kazerin, Israel
| | - Arava Aderet
- GGA - Galil Genetic Analysis Ltd, P.O.Box 3664, 12900, Kazerin, Israel
| | - Daniel Baumel
- GGA - Galil Genetic Analysis Ltd, P.O.Box 3664, 12900, Kazerin, Israel
| | - Efrat Kellerman
- GGA - Galil Genetic Analysis Ltd, P.O.Box 3664, 12900, Kazerin, Israel
| | - Yoram Plotsky
- GGA - Galil Genetic Analysis Ltd, P.O.Box 3664, 12900, Kazerin, Israel
| | - Oshrat Noked Partouche
- Shamir Research Institute, University of Haifa, P.O.Box 97, 1290000, Kazerin, Israel.,Tel Hai College, 12210, Tel-Hai, Israel
| | - Gal Elhalal
- Vetmarket Ltd. Industrial Park Hevel Modiin, P.O.Box 960, 6085001, Shoham, Israel
| | - Izhar Ben-Shlomo
- Zefat Academic College, Zefat, Israel.,Faculty of Medicine in the Galilee, Bar-Ilan University & Baruch Padeh Medical Center, Poria, Israel
| | - Dani Bercovich
- Tel Hai College, 12210, Tel-Hai, Israel.,GGA - Galil Genetic Analysis Ltd, P.O.Box 3664, 12900, Kazerin, Israel
| |
Collapse
|
33
|
Davidson G. Veterinary Compounding: Regulation, Challenges, and Resources. Pharmaceutics 2017; 9:pharmaceutics9010005. [PMID: 28075379 PMCID: PMC5374371 DOI: 10.3390/pharmaceutics9010005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Revised: 12/20/2016] [Accepted: 01/04/2017] [Indexed: 11/16/2022] Open
Abstract
The spectrum of therapeutic need in veterinary medicine is large, and the availability of approved drug products for all veterinary species and indications is relatively small. For this reason, extemporaneous preparation, or compounding, of drugs is commonly employed to provide veterinary medical therapies. The scope of veterinary compounding is broad and focused primarily on meeting the therapeutic needs of companion animals and not food-producing animals in order to avoid human exposure to drug residues. As beneficial as compounded medical therapies may be to animal patients, these therapies are not without risks, and serious adverse events may occur from poor quality compounds or excipients that are uniquely toxic when administered to a given species. Other challenges in extemporaneous compounding for animals include significant regulatory variation across the global veterinary community, a relative lack of validated compounding formulas for use in animals, and poor adherence by compounders to established compounding standards. The information presented in this article is intended to provide an overview of the current landscape of compounding for animals; a discussion on associated benefits, risks, and challenges; and resources to aid compounders in preparing animal compounds of the highest possible quality.
Collapse
Affiliation(s)
- Gigi Davidson
- Clinical Pharmacy Services, North Carolina State University, College of Veterinary Medicine, Raleigh, NC 27607, USA.
| |
Collapse
|
34
|
Long WM, Sinnott VB, Bracker K, Thomas D. Use of 20% intravenous lipid emulsion for the treatment of loperamide toxicosis in a Collie homozygous for the ABCB1-1∆ mutation. J Vet Emerg Crit Care (San Antonio) 2016; 27:357-361. [PMID: 27992655 DOI: 10.1111/vec.12562] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Revised: 05/14/2016] [Accepted: 06/09/2015] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To describe the successful treatment of loperamide toxicosis in a dog using intravenous lipid emulsion (ILE). CASE SUMMARY An 8-month-old male neutered Rough Collie weighing 20.0 kg was given a total dose of 0.75 mg/kg loperamide over 3 days as treatment for diarrhea. The dog was subsequently evaluated for signs of dull mentation, anxiety, ptyalism and ataxia, thought to be a result of loperamide intoxication. The dog was treated with a 1.5 mL/kg IV bolus of 20% ILE solution followed by 0.25 mL/kg/min of the same solution for 2 hours. The dog's mentation improved rapidly following ILE infusion, and he was neurologically normal 3 hours after initiation of ILE treatment. The dog was subsequently found to be homozygous for the ATP-binding cassette (ABC) transporter gene (ABCB1-1∆) mutation. There were no adverse effects noted during or following ILE infusion. NEW OR UNIQUE INFORMATION PROVIDED ILE was successful in the treatment of loperamide toxicosis in a Collie with the ABCB1-1∆ mutation. ILE may be of benefit for treatment of other intoxications in dogs with ABCB1-1Δ mutations.
Collapse
Affiliation(s)
- Whitney M Long
- Angell Animal Medical Center, 350 South Huntington Avenue, Boston, MA, 02130
| | - Virginia B Sinnott
- Angell Animal Medical Center, 350 South Huntington Avenue, Boston, MA, 02130
| | - Kiko Bracker
- Angell Animal Medical Center, 350 South Huntington Avenue, Boston, MA, 02130
| | - Danielle Thomas
- Angell Animal Medical Center, 350 South Huntington Avenue, Boston, MA, 02130
| |
Collapse
|
35
|
Simon BT, Steagall PV. The present and future of opioid analgesics in small animal practice. J Vet Pharmacol Ther 2016; 40:315-326. [DOI: 10.1111/jvp.12377] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Accepted: 09/25/2016] [Indexed: 11/30/2022]
Affiliation(s)
- B. T. Simon
- Department of Small Animal Clinical Sciences; College of Veterinary Medicine and Biomedical Sciences; Texas A&M University; College Station TX USA
| | - P. V. Steagall
- Department of Clinical Sciences; Faculty of Veterinary Medicine; Université de Montréal; Saint-Hyacinthe QC Canada
| |
Collapse
|
36
|
Childress MO, Ramos-Vara JA, Ruple A. A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas. J Am Vet Med Assoc 2016; 249:1067-1078. [DOI: 10.2460/javma.249.9.1067] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
37
|
Firdova Z, Turnova E, Bielikova M, Turna J, Dudas A. The prevalence of ABCB1:c.227_230delATAG mutation in affected dog breeds from European countries. Res Vet Sci 2016; 106:89-92. [DOI: 10.1016/j.rvsc.2016.03.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 02/24/2016] [Accepted: 03/28/2016] [Indexed: 10/22/2022]
|
38
|
Lawrence J, Cameron D, Argyle D. Species differences in tumour responses to cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci 2016; 370:rstb.2014.0233. [PMID: 26056373 DOI: 10.1098/rstb.2014.0233] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Despite advances in chemotherapy, radiotherapy and targeted drug development, cancer remains a disease of high morbidity and mortality. The treatment of human cancer patients with chemotherapy has become commonplace and accepted over the past 100 years. In recent years, and with a similar incidence of cancer to people, the use of cancer chemotherapy drugs in veterinary patients such as the dog has also become accepted clinical practice. The poor predictability of tumour responses to cancer chemotherapy drugs in rodent models means that the standard drug development pathway is costly, both in terms of money and time, leading to many drugs failing in Phase I and II clinical trials. This has led to the suggestion that naturally occurring cancers in pet dogs may offer an alternative model system to inform rational drug development in human oncology. In this review, we will explore the species variation in tumour responses to conventional chemotherapy and highlight our understanding of the differences in pharmacodynamics, pharmacokinetics and pharmacogenomics between humans and dogs. Finally, we explore the potential hurdles that need to be overcome to gain the greatest value from comparative oncology studies.
Collapse
Affiliation(s)
- Jessica Lawrence
- Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush EH25 9RG, UK
| | - David Cameron
- University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh EH4 2LF, UK
| | - David Argyle
- Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush EH25 9RG, UK
| |
Collapse
|
39
|
Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med 2015; 29:1-6. [PMID: 25619511 PMCID: PMC4858061 DOI: 10.1111/jvim.12525] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2014] [Revised: 10/08/2014] [Accepted: 11/17/2014] [Indexed: 02/05/2023] Open
Abstract
Drug–drug interactions can cause unanticipated patient morbidity and mortality. The consequences of drug–drug interactions can be especially severe when anticancer drugs are involved because of their narrow therapeutic index. Veterinary clinicians have traditionally been taught that drug–drug interactions result from alterations in drug metabolism, renal excretion or protein binding. More recently, drug–drug interactions resulting from inhibition of P‐glycoprotein‐mediated drug transport have been identified in both human and veterinary patients. Many drugs commonly used in veterinary patients are capable of inhibiting P‐glycoprotein function and thereby causing an interaction that results in severe chemotherapeutic drug toxicity. The intent of this review is to describe the mechanism and clinical implications of drug–drug interactions involving P‐glycoprotein and anticancer drugs. Equipped with this information, veterinarians can prevent serious drug–drug interactions by selecting alternate drugs or adjusting the dose of interacting drugs.
Collapse
Affiliation(s)
- K L Mealey
- Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA
| | | |
Collapse
|
40
|
Gookin JL, Correa MT, Peters A, Malueg A, Mathews KG, Cullen J, Seiler G. Association of Gallbladder Mucocele Histologic Diagnosis with Selected Drug Use in Dogs: A Matched Case-Control Study. J Vet Intern Med 2015; 29:1464-72. [PMID: 26478445 PMCID: PMC4895658 DOI: 10.1111/jvim.13649] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Revised: 09/03/2015] [Accepted: 09/17/2015] [Indexed: 02/04/2023] Open
Abstract
Background The cause of gallbladder mucocele (GBM) formation in dogs currently is unknown. Many available drugs represent a newer generation of xenobiotics that may predispose dogs to GBM formation. Objective To determine if there is an association between the histologic diagnosis of GBM in dogs and administration of selected drugs. Animals Eighty‐one dogs with a histologic diagnosis of GBM and 162 breed, age, and admission date‐matched control dogs from a single referral institution. Methods Medical records of dogs with GBM and control dogs from 2001 to 2011 were reviewed. Owner verification of drug history was sought by a standard questionnaire. Reported use of heartworm, flea, and tick preventatives as well as nonsteroidal anti‐inflammatory drugs, analgesics, corticosteroids, or medications for treatment of osteoarthritis was recorded. Results Dogs with GBM were 2.2 times as likely to have had reported use of thyroxine (as a proxy for the diagnosis of hypothyroidism) as control dogs (95% confidence interval [CI], 0.949–5.051), 3.6 times as likely to have had reported treatment for Cushing's disease (95% CI, 1.228–10.612), and 2.3 times as likely to have had reported use of products containing imidacloprid (95% CI, 1.094–4.723). Analysis of a data subset containing only Shetland sheepdogs (23 GBM and 46 control) indicated that Shetland sheepdogs with GBM formation were 9.3 times as likely to have had reported use of imidacloprid as were control Shetland sheepdogs (95% CI, 1.103–78.239). Conclusions and Clinical Importance This study provides evidence for an association between selected drug use and GBM formation in dogs. A larger epidemiologic study of Shetland sheepdogs with GBM formation and exposure to imidacloprid is warranted.
Collapse
Affiliation(s)
- J L Gookin
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - M T Correa
- Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - A Peters
- The Veterinary Hospital, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - A Malueg
- The Veterinary Hospital, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - K G Mathews
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - J Cullen
- Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| | - G Seiler
- Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
| |
Collapse
|
41
|
Zhu M, Yancy HF, Deaver C, Jones YL, Myers MJ. Loperamide-induced expression of immune and inflammatory genes in Collies associated with ivermectin sensitivity. J Vet Pharmacol Ther 2015; 39:131-7. [PMID: 26471945 DOI: 10.1111/jvp.12268] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Accepted: 08/11/2015] [Indexed: 12/16/2022]
Abstract
This study evaluated the impact of the ABCB1-1Δ mutation in Collies which exhibited toxicity toward ivermectin, on changes in gene expression when given the unrelated ABCB1 substrate loperamide, to identify potential biomarkers predictive of drug safety. Thirty-two healthy intact Collies consisting of dogs with either a wild-type, heterozygous mutant, or homozygous mutant genotype were used. Whole blood samples were collected from Collies at 0 or 5 h following administration of loperamide at a dose of 0.10 mg/kg. Whole-genome gene expression microarray was conducted to examine for changes in gene expression. Microarray analysis identified loperamide-induced changes in gene expression which were specifically associated with ivermectin-sensitive phenotypes in Collies possessing the ABCB1-1Δ mutation. Gene pathway analysis further demonstrated that the altered genes are involved in immunological disease, cell death and survival, and cellular development. Thirteen genes, including CCL8 and IL-8, were identified. Collie dogs harboring ABCB1-1Δ mutation which also exhibited toxicity toward ivermectin demonstrated systematic responses following loperamide treatment exhibited by altered expression of genes involved in immune and inflammatory signaling pathways. Genes such as CCL8 and IL-8 are potential biomarkers in whole blood that may predict the safety of loperamide in dogs with ABCB1-1∆ mutation associated with ivermectin sensitivity.
Collapse
Affiliation(s)
- M Zhu
- U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Research, Laurel, MD, USA
| | - H F Yancy
- U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Research, Laurel, MD, USA
| | - C Deaver
- U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Research, Laurel, MD, USA
| | - Y L Jones
- U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Research, Laurel, MD, USA
| | - M J Myers
- U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Research, Laurel, MD, USA
| |
Collapse
|
42
|
Howard JT, O’Nan AT, Maltecca C, Baynes RE, Ashwell MS. Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine. PLoS One 2015; 10:e0137830. [PMID: 26366864 PMCID: PMC4569569 DOI: 10.1371/journal.pone.0137830] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Accepted: 08/24/2015] [Indexed: 11/19/2022] Open
Abstract
Characterizing the variability in transcript levels across breeds and sex in swine for genes that play a role in drug metabolism may shed light on breed and sex differences in drug metabolism. The objective of the study is to determine if there is heterogeneity between swine breeds and sex in transcript levels for genes previously shown to play a role in drug metabolism for animals administered flunixin meglumine or fenbendazole. Crossbred nursery female and castrated male pigs (n = 169) spread across 5 groups were utilized. Sires (n = 15) of the pigs were purebred Duroc, Landrace, Yorkshire or Hampshire boars mated to a common sow population. Animals were randomly placed into the following treatments: no drug (control), flunixin meglumine, or fenbendazole. One hour after the second dosing, animals were sacrificed and liver samples collected. Quantitative Real-Time PCR was used to measure liver gene expression of the following genes: SULT1A1, ABCB1, CYP1A2, CYP2E1, CYP3A22 and CYP3A29. The control animals were used to investigate baseline transcript level differences across breed and sex. Post drug administration transcript differences across breed and sex were investigated by comparing animals administered the drug to the controls. Contrasts to determine fold change were constructed from a model that included fixed and random effects within each drug. Significant (P-value <0.007) basal transcript differences were found across breeds for SULT1A1, CYP3A29 and CYP3A22. Across drugs, significant (P-value <0.0038) transcript differences existed between animals given a drug and controls across breeds and sex for ABCB1, PS and CYP1A2. Significant (P <0.0038) transcript differences across breeds were found for CYP2E1 and SULT1A1 for flunixin meglumine and fenbendazole, respectively. The current analysis found transcript level differences across swine breeds and sex for multiple genes, which provides greater insight into the relationship between flunixin meglumine and fenbendazole and known drug metabolizing genes.
Collapse
Affiliation(s)
- Jeremy T. Howard
- Department of Animal Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC, United States of America
| | - Audrey T. O’Nan
- Department of Animal Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC, United States of America
| | - Christian Maltecca
- Department of Animal Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC, United States of America
| | - Ronald E. Baynes
- Department of Population Health and Pathobiology, Center for Chemical Toxicology and Research Pharmacokinetics, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States of America
| | - Melissa S. Ashwell
- Department of Animal Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC, United States of America
- * E-mail:
| |
Collapse
|
43
|
International Veterinary Epilepsy Task Force's current understanding of idiopathic epilepsy of genetic or suspected genetic origin in purebred dogs. BMC Vet Res 2015; 11:175. [PMID: 26316206 PMCID: PMC4552344 DOI: 10.1186/s12917-015-0463-0] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 06/29/2015] [Indexed: 12/20/2022] Open
Abstract
Canine idiopathic epilepsy is a common neurological disease affecting both purebred and crossbred dogs. Various breed-specific cohort, epidemiological and genetic studies have been conducted to date, which all improved our knowledge and general understanding of canine idiopathic epilepsy, and in particular our knowledge of those breeds studied. However, these studies also frequently revealed differences between the investigated breeds with respect to clinical features, inheritance and prevalence rates. Awareness and observation of breed-specific differences is important for successful management of the dog with epilepsy in everyday clinical practice and furthermore may promote canine epilepsy research. The following manuscript reviews the evidence available for breeds which have been identified as being predisposed to idiopathic epilepsy with a proven or suspected genetic background, and highlights different breed specific clinical features (e.g. age at onset, sex, seizure type), treatment response, prevalence rates and proposed inheritance reported in the literature. In addition, certain breed-specific diseases that may act as potential differentials for idiopathic epilepsy are highlighted.
Collapse
|
44
|
Monobe MM, Junior JPA, Lunsford KV, Silva RC, Bulla C. Frequency of the MDR1 mutant allele associated with multidrug sensitivity in dogs from Brazil. VETERINARY MEDICINE-RESEARCH AND REPORTS 2015; 6:111-117. [PMID: 30101099 PMCID: PMC6067530 DOI: 10.2147/vmrr.s72373] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
To date, a 4-bp deletion in the MDR1 gene has been detected in more than ten dog breeds, as well as in mixed breed dogs, in several countries, however information regarding this mutation in dogs from Brazil is lacking. For this reason, 103 Collies, 77 Border Collies, 76 Shetland Sheepdogs, 20 Old English Sheepdogs, 55 German Shepherds, 16 Australian Shepherds, and 53 Whippets from Brazil were screened for the presence of the mutation. The heterozygous mutated genotype, MDR1 (+/−), frequency found for Collies, Australian Shepherd, and Shetland Sheepdog was 50.5% (95% CI =41.1%–59.9%), 31.3% (95% CI =8.6%–53.2%), and 15.8% (95% CI =7.7%–23.9%), respectively. Homozygous mutated genotype, MDR1 (−/−), was detected only in Collies 35.9%. The MDR1 allele mutant frequency found for Collies, Australian Shepherd, and Shetland Sheepdog was 61.2% (95% CI =54.8%–67.5%), 15.6% (95% CI =3.1%–28.2%), and 7.9% (95% CI =3.7%–12.1%), respectively. Additionally, even free of the mutant allele, the maximum mutant prevalence (MMP) in that population, with 95% CI, was 3.8%, 5.2%, 5.4%, and 13.8% for Border Collies, German Shepherds, Whippets, and Old English Sheepdogs, respectively. In this way, this information is important, not only for MDR1 genotype-based breeding programs and international exchange of breeding animals of predisposed breeds, but also for modification of drug therapy for breeds at risk.
Collapse
Affiliation(s)
- Marina M Monobe
- Department of Veterinary Clinics, School of Veterinary Medicine and Animal Science
| | - João P Araujo Junior
- Department of Microbiology and Immunology, Biosciences Institute, Sao Paulo State University (UNESP), Botucatu, Brazil
| | | | - Rodrigo C Silva
- Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi, MS, USA,
| | - Camilo Bulla
- Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi, MS, USA,
| |
Collapse
|
45
|
Abstract
Cancer is increasingly more common. Several tests for the diagnosis and treatment of cancer in companion animals have been developed. Screening tests discussed include those for lymphoid neoplasia, hemangiosarcoma, and transitional cell carcinoma of the bladder. None of these tests should be used in isolation for diagnosis. Vincristine and doxorubicin are mainstays in the treatment of canine lymphoma. However, it is important and accepted practice to test individuals of predisposed breeds for this mutation before administering these drugs in a lymphoma protocol.
Collapse
Affiliation(s)
- Stephanie E Schleis
- Department of Clinical Sciences, Bailey Small Animal Teaching Hospital, Auburn University, 1010 Wire Road, Auburn, AL 36839, USA.
| |
Collapse
|
46
|
Higginbotham ML, McCaw DL, Roush JK, Nietfeld JC, Wilkerson MJ, Reeds K, Burr D. Intermittent Single-Agent Doxorubicin for the Treatment of Canine B-Cell Lymphoma. J Am Anim Hosp Assoc 2013; 49:357-62. [DOI: 10.5326/jaaha-ms-5929] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Canine B-cell lymphoma is a highly treatable disease, but cost and logistical factors may hamper an owner’s ability to pursue treatment of their pet with this disease. The authors evaluated the use of single-agent doxorubicin in an intermittent fashion for efficacy in the treatment of this disease. Morphologic and clinical data were analyzed for prognostic significance. Eighteen dogs with B-cell lymphoma, all with multicentric disease, were enrolled. The overall complete response (CR) rate was 78%, median total doxorubicin remission time (TDR) was 80.5 days, and median overall survival (OS) was 169.5 days. The median number of doxorubicin doses administered was 4.5. First remission times were significantly affected by clinical stage and substage of disease. Outcome for the dogs in this study were similar to those previously reported for single-agent doxorubicin treatment. Additionally, the intermittent nature of the treatments made the described protocol more feasible for the owners who enrolled their pets in this study. Intermittent single-agent doxorubicin is not a substitute for multiagent chemotherapy protocols in the treatment of canine lymphoma; however, it is a reasonable alternative if the cost and time commitments are limiting factors for an owner.
Collapse
Affiliation(s)
- Mary Lynn Higginbotham
- Department of Clinical Sciences (M.H., D.M., K.R., J.R., D.B.) and Department of Diagnostic Medicine/Pathobiology (J.N., M.W.), College of Veterinary Medicine, Kansas State University, Manhattan, KS; and Boren Veterinary Medical Teaching Hospital, Stillwater, OK (K.R.)
| | - Dudley L. McCaw
- Department of Clinical Sciences (M.H., D.M., K.R., J.R., D.B.) and Department of Diagnostic Medicine/Pathobiology (J.N., M.W.), College of Veterinary Medicine, Kansas State University, Manhattan, KS; and Boren Veterinary Medical Teaching Hospital, Stillwater, OK (K.R.)
| | - James K. Roush
- Department of Clinical Sciences (M.H., D.M., K.R., J.R., D.B.) and Department of Diagnostic Medicine/Pathobiology (J.N., M.W.), College of Veterinary Medicine, Kansas State University, Manhattan, KS; and Boren Veterinary Medical Teaching Hospital, Stillwater, OK (K.R.)
| | - Jerome C. Nietfeld
- Department of Clinical Sciences (M.H., D.M., K.R., J.R., D.B.) and Department of Diagnostic Medicine/Pathobiology (J.N., M.W.), College of Veterinary Medicine, Kansas State University, Manhattan, KS; and Boren Veterinary Medical Teaching Hospital, Stillwater, OK (K.R.)
| | - Melinda J. Wilkerson
- Department of Clinical Sciences (M.H., D.M., K.R., J.R., D.B.) and Department of Diagnostic Medicine/Pathobiology (J.N., M.W.), College of Veterinary Medicine, Kansas State University, Manhattan, KS; and Boren Veterinary Medical Teaching Hospital, Stillwater, OK (K.R.)
| | - Kimberly Reeds
- Department of Clinical Sciences (M.H., D.M., K.R., J.R., D.B.) and Department of Diagnostic Medicine/Pathobiology (J.N., M.W.), College of Veterinary Medicine, Kansas State University, Manhattan, KS; and Boren Veterinary Medical Teaching Hospital, Stillwater, OK (K.R.)
| | - Diana Burr
- Department of Clinical Sciences (M.H., D.M., K.R., J.R., D.B.) and Department of Diagnostic Medicine/Pathobiology (J.N., M.W.), College of Veterinary Medicine, Kansas State University, Manhattan, KS; and Boren Veterinary Medical Teaching Hospital, Stillwater, OK (K.R.)
| |
Collapse
|
47
|
Mealey KL. Adverse Drug Reactions in Veterinary Patients Associated with Drug Transporters. Vet Clin North Am Small Anim Pract 2013; 43:1067-78. [DOI: 10.1016/j.cvsm.2013.04.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
48
|
Huang HP, Lien YH. Treatment of canine generalized demodicosis associated with hyperadrenocorticism with spot-on moxidectin and imidacloprid. Acta Vet Scand 2013; 55:40. [PMID: 23663380 PMCID: PMC3663785 DOI: 10.1186/1751-0147-55-40] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2012] [Accepted: 05/03/2013] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Canine generalized demodicosis associated with hyperadrenocorticism is often problematic and might be intractable. The aim of this study was to report the efficacy of a weekly application of spot-on moxidectin/imidacloprid in dogs with hyperadrenocorticism and secondary generalized demodicosis. METHODS Dogs with hyperadrenocorticism and secondary generalized demodicosis were included. The condition of hyperadrenocorticism was treated and stabilized with trilostane before and throughout the study period in all dogs. RESULTS Average total live adult mite counts before treatment and after four, eight and 12 weeks of spot-on moxidectin/imidacloprid (2.5/10 mg/kg) applications were 20.1±6.3 (range, 13-33), 0.5±0.7 (range, 0-2; 6/11 were negative), 0.2±0.4 (range, 0-1; 9/11 were negative), 0.2±0.4 (range, 0-1; 9/11 were negative) and 0.1±0.3 (range, 0-1; 10/11 were negative) respectively; this difference was significant (P<0.001). Ten of 11 dogs (90.1%) achieved clinical remission, as demonstrated by the absence of demodectic mites at any life stage at monthly scrapings for eight consecutive weeks, and maintained remission throughout the 12-month follow-up period. CONCLUSION The weekly application of spot-on moxidectin/imidacloprid appeared to be effective and safe against generalized adult onset canine demodicosis associated with hyperadrenocorticism.
Collapse
Affiliation(s)
- Hui-Pi Huang
- Institute of Veterinary Clinical Science, Veterinary School, National Taiwan University, Roosevelt Road, Taipei 106, Taiwan
| | - Yu-Hsin Lien
- Azu Clinic for Animals, KinShan South Road 100, Taipei, Taiwan
| |
Collapse
|
49
|
Waite A, Balkman C, Bailey D, Kiselow M, Flory A, Beaulieu BB, Lewis LD, McEntee M. Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer. Vet Comp Oncol 2012; 12:160-8. [PMID: 22905693 DOI: 10.1111/j.1476-5829.2012.00350.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2012] [Revised: 07/06/2012] [Accepted: 07/25/2012] [Indexed: 11/30/2022]
Abstract
The goal of the current study was to determine the efficacy of oral docetaxel in combination with cyclosporine in the treatment of canine epithelial cancer. Requirements for eligibility were histological confirmation of epithelial neoplasia, measurable disease, no chemotherapy treatment within 2 weeks, and a life expectancy of ≥ 3 months. Fifty-one dogs were enrolled. All dogs received 1.625 mg kg(-1) of docetaxel with 5 mg kg(-1) of cyclosporine (DT/CSA) by gavage. Ten dogs had progressive disease at 2 weeks, one dog died, and one dog was withdrawn from the study. Thirty-nine dogs were given a second dose of DT/CSA, three each receiving a third or fourth dose. Eight dogs had a dose reduction (1.5 mg kg(-1)) and six dogs had treatment delays primarily for gastrointestinal toxicity. The overall response rate was 16.7% (8/48 had a partial response there were no complete responses). The highest response rate was seen in dogs with oral squamous cell carcinoma (50%; 6/12).
Collapse
Affiliation(s)
- A Waite
- Cornell University Hospital for Animals, College of Veterinary Medicine, Ithaca, NY, USA
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Tappin SW, Goodfellow MR, Peters IR, Day MJ, Hall EJ, Mealey KL. Frequency of the mutant MDR1
allele in dogs in the UK. Vet Rec 2012; 171:72. [DOI: 10.1136/vr.100633] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- S. W. Tappin
- School of Veterinary Sciences; University of Bristol; Langford North Somerset BS40 5DU UK
| | - M. R. Goodfellow
- School of Veterinary Sciences; University of Bristol; Langford North Somerset BS40 5DU UK
| | - I. R. Peters
- School of Veterinary Sciences; University of Bristol; Langford North Somerset BS40 5DU UK
| | - M. J. Day
- School of Veterinary Sciences; University of Bristol; Langford North Somerset BS40 5DU UK
| | - E. J. Hall
- School of Veterinary Sciences; University of Bristol; Langford North Somerset BS40 5DU UK
| | - K. L. Mealey
- Department of Veterinary Clinical Sciences; Washington State University; Pullman WA 99164 USA
| |
Collapse
|